Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001415889-24-026168
Filing Date
2024-11-05
Accepted
2024-11-05 17:00:15
Documents
1
Period of Report
2024-09-23

Document Format Files

Seq Description Document Type Size
1 form4a-11052024_051110.html 4/A  
1 form4a-11052024_051110.xml 4/A 4040
  Complete submission text file 0001415889-24-026168.txt   5746
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS INC., 3 UNIVERSITY PLAZA DRIVE, STE 320 HACKENSACK NJ 07601
Business Address
Rubin Eyal (Reporting) CIK: 0001721411 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-33357 | Film No.: 241428384